Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 1× · first seen 13-sep-2026 · last seen 13-sep-2026

PD-L2 Checkpoint Blockade

Current understanding

To be populated as evidence accumulates.

Evidence log

  • 2026-09-10 — Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction.: Aged-mouse study: PD-L2 is upregulated on senescent cells and shields them from immune clearance; both genetic PD-L2 knockout and anti-PD-L2 antibody therapy reduced senescent-cell burden and restored insulin sensitivity and grip strength in aged mice — establishes PD-L2 as a senescence-immune-evasion checkpoint and an immuno-senolytic-adjacent target. [animal-model] (novelty: 4)

Open questions

Related

Contributing findings

pubmed preclinical animal-model
Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction.
10-sep-2026 novelty 4 per-area 4 strengthens

build build 880 · 2bcef25 · 2026-11-18